Shareholders approve the election of all three athira director nominees at 2022 annual meeting

Bothell, wash., may 19, 2022 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced, based on the preliminary vote count provided by its proxy solicitor, that athira's shareholders have approved the election of all three of athira's highly qualified, independent director nominees – joseph edelman, john m. fluke, jr. and grant pickering – to the company's board of directors.
ATHA Ratings Summary
ATHA Quant Ranking